Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine David BerdHenry C. Maguire Jr.George Murphy Original Articles Pages: 141 - 147
Enhanced in vivo sensitivity to interferon with in vitro resistant B16 tumor cells in mice Christina M. FleischmannG. John StantonW. Robert Fleischmann Jr Original Articles Pages: 148 - 154
Comparative study of inhibitory effects by murine interferon γ and a new bisphosphonate (alendronate) in hypercalcemic, nude mice bearing human tumor (LJC-1-JCK) Masahiro TohkinShinji KakudoHitoshi Arita Original Articles Pages: 155 - 160
Increased proliferation of a human breast carcinoma cell line by recombinant interleukin-2 Mitsuo KatanoTatsuya MatsuoJutaro Tadano Original Articles Pages: 161 - 166
Reversible anergy in circulating lymphocytes of cancer patients during interleukin-2 therapy Emilio ClementiEraldo BucciClaudio Fortis Original Articles Pages: 167 - 171
Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma Takashi MorisakiDonald L. MortonDave S. B. Hoon Original Articles Pages: 172 - 178
Enhanced killing capacity of human Kupffer cells after activation with human granulocyte/macrophage-colony-stimulating factor and interferon γ B. SchuurmanG. HeuffS. Meyer Original Articles Pages: 179 - 184
In vitro inhibition of natural-killer-mediated lysis by chromatin fragments Anne Dominique Le LannGilbert Jean FourniéHervé Benoist Original Articles Pages: 185 - 192
Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients Amerigo BoiardiAntonio SilvaniAndrea Salmaggi Original Articles Pages: 193 - 197
Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody Paul B. ChapmanStephen D. GilliesRegina M. Reilly Original Articles Pages: 198 - 204
“Spontaneous” regressions of a metastatic adenocarcinoma transmitted by a cadaver kidney graft: Support for immunotherapy? F. VincentV. LevyB. Leclercq Letter to the Editors Pages: 205 - 206